Thrombosis Australia

Thrombosis Australia is a central information and resource hub for the community proudly brought to you by the Perth Blood Institute



Our Thrombosis Australia Advisory Panel consists of seven eminent Australian healthcare professionals.

Thrombosis Australia Advisory Panel

If you are a healthcare professional you can access the Thrombosis Australia Professionals site here:

Thrombosis Australia Professionals


Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge.

The study found that extended post-discharge thromboprophylaxis with rivaroxaban for 35 days when compared with no anticoagulation, resulted in better clinical outcomes, including a reduction in major and fatal thromboembolic events without increasing major bleeding.

(thromboprophylaxis - any preventive measure that reduces the likelihood of the formation of blood clots)

To view the complete research article "Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19" click HERE.